LOCM yields 1000000.00% · ABBV yields 3.06%● Live data
📍 LOCM pulled ahead of the other in Year 1
Combined, LOCM + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LOCM + ABBV for your $10,000?
Local Corporation, a technology and advertising company, provides search results to consumers who search online for local businesses, products, and services in the United States. The company offers various local search advertising products and services comprising Local.com, a Website and app, which reaches approximately 20 million monthly unique visitors (MUVs); hosted network, a database of local business and product listings along with ad feeds, which consists of approximately 1,000 partner Websites and reaches approximately 5 million MUVs; syndication network, an ad feed solution; and display and pre-roll video networks that provide advertisers with additional reach and exposure for brands through distribution of customized display and pre-roll ads. It also provides pay-per-click, pay-per-call, and display ad units through its search results; and photographs, user ratings and reviews, video, coupons, hours of operations, and others to users of its Websites and network partner Websites, as well as third party partners. The company was formerly known as Local.com Corporation and changed its name to Local Corporation in September 2012. Local Corporation was founded in 1999 and is headquartered in Irvine, California.
Full LOCM Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.